Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 10, 2025 16:02 ET | Source: Ardelyx, Inc.

Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings

WALTHAM, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
April 10, 2025 08:31 ET | Source: Sixty Degrees Pharmaceuticals

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

60 Degrees Pharma CEO Geoff Dow, PhD, will discuss babesiosis threats and therapies at the virtual Healing Lyme Summit, April 15–21
April 09, 2025 07:00 ET | Source: Augustine Therapeutics

Augustine Therapeutics appoints Industry Veteran Pascale Witz as Chair of its Board of Directors

New Chair brings more than three decades of life sciences industry experience, with a successful track record as a biotech company board memberSignificant leadership experience will be instrumental as...
April 09, 2025 01:00 ET | Source: Augustine Therapeutics

Augustine Therapeutics appoints Industry Veteran Pascale Witz as Chair of its Board of Directors

New Chair brings more than three decades of life sciences industry experience, with a successful track record as a biotech company board memberSignificant leadership experience will be instrumental as...
April 08, 2025 08:31 ET | Source: Sixty Degrees Pharmaceuticals

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

60 Degrees Pharma partners with Yale to develop tafenoquine for treating and preventing babesiosis, a severe tick-borne disease with limited treatments.
March 31, 2025 16:03 ET | Source: Ardelyx, Inc.

Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings

WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
March 28, 2025 18:06 ET | Source: Knight Therapeutics

Knight Therapeutics Inc. ranks on The Globe and Mail’s sixth-annual Women Lead Here benchmark of executive gender diversity

MONTREAL, March 28, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it will be recognized on The Globe and Mail’s 2025 Report on...
March 28, 2025 18:06 ET | Source: Thérapeutique Knight inc.

Thérapeutique Knight inc. se mérite une place à la sixième édition du classement Women Lead Here du Globe and Mail sur la diversité des femmes cadres

MONTRÉAL, 28 mars 2025 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight » ou « la Société ») a le plaisir d’annoncer sa nomination à la sixième liste annuelle Women Lead Here du...
March 28, 2025 06:59 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces 2024 Annual Results

60 Degrees Pharmaceuticals (SXTP) reported 140% revenue growth in 2024, driven by Arakoda® sales. Clinical trials and market expansion efforts continue.
March 26, 2025 08:00 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses

CAMBRIDGE, Mass. and HOUSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of...